Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib and Trastuzumab vs Chemotherapy and Trastuzumab in HER2+ MBC (GIM12-TYPHER)
NCT02238509Phase 2Unknown
- Sponsor
- Consorzio Oncotech
- Start
- Nov 2014
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lapatinib in HER2-positive metastatic breast cancer, sponsored by Consorzio Oncotech. Status: unknown.
02
Drugs
lapatinib
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT02238509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02238509.